Vetnostrum Animal Health Co., Ltd.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. carries a market capitalization of 2.38B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. has 72.80M shares outstanding.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. trades at a trailing price-to-earnings ratio of 16.60. The price-to-sales ratio is 1.65, and the price-to-book ratio stands at 1.80.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. trades at an EV/EBITDA multiple of 7.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.00 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Vetnostrum Animal Health Co., Ltd. trades at an EV/FCF ratio of 10.17, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.95B versus a market cap of 2.38B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. maintains a current ratio of 2.62, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.59, indicating elevated leverage, while an interest coverage ratio of 589.12 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Vetnostrum Animal Health Co., Ltd. posted a return on equity (ROE) of 11.53, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.80 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.80, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.25, useful for judging operating efficiency across full business cycles. The company generates approximately 7.50M in revenue per employee across its workforce of 192.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.38 indicates how many times Vetnostrum Animal Health Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Vetnostrum Animal Health Co., Ltd. recorded 36.53M in income tax expense. That works out to an effective tax rate of 20.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 180.12M, leaving 143.59M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Vetnostrum Animal Health Co., Ltd.'s stock has declined approximately 15.71% over the past 52 weeks. The 50-day moving average sits at 32.25, while the 200-day moving average is 33.71.

Over the twelve months ended June 30, 2026, Vetnostrum Animal Health Co., Ltd. generated 1.44B in revenue and converted that into 143.59M in net income, yielding earnings per share of 1.97. EBITDA reached 249.20M, while operating income came in at 177.01M.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. holds 458.92M in cash and equivalents against 21.06M in total debt, resulting in a net debt position of -137.34M. Total book value stands at 1.33B, with working capital of 700.78M providing operational flexibility.

Vetnostrum Animal Health Co., Ltd. produced 219.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -28.10M in capital expenditures, free cash flow totaled 191.06M - equivalent to 2.63 per share.

Over the twelve months ended June 30, 2026, Vetnostrum Animal Health Co., Ltd. posted a gross margin of 34.47, reflecting its pricing power and cost economics. The operating margin of 12.26 and net profit margin of 9.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Vetnostrum Animal Health Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -7.35, meaning Vetnostrum Animal Health Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Vetnostrum Animal Health Co., Ltd. has an Altman Z-Score of 5.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.